Special Issue "Oligonucleotides-Based Therapeutics"
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 57019
Interests: oligonucleotides-based therapeutics; peptide (cell penetrating peptides)-based delivery vectors; antisense oligonucleotides cellular trafficking
Special Issues, Collections and Topics in MDPI journals
Antisense oligonucleotides and small interfering RNAs are widely used tools to regulate sequence-specifically gene expression. Although envisaged early on, clinical developments turned out more difficult to implement and the first successes have been documented only in the last few years. More recently, other nucleic acids-based strategies to regulate (or promote) gene expression have been proposed, including micro RNAs (or miRNA antagonists), splice switching oligonucleotides, immune-regulating oligonucleotides and messenger RNAs. Several FDA-approved drugs as well as promising clinical trials for the treatment of several diseases or for vaccine development have emerged. Reviews and original research articles dealing with fundamental research, the improvement of pharmacological properties (specificity of target recognition and delivery in particular), as well as pre-clinical development and clinical applications will be welcomed.
Dr. Bernard Lebleu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antisense oligonucleotides
- RNA interference
- splicing regulation
- messenger RNA
- oligonucleotides trafficking